Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Estropipate 3 Mg Tabs 100 By Actavis Pharma.

Image 0 of Estropipate 3 Mg Tabs 100 By Actavis Pharma.Image 1 of Estropipate 3 Mg Tabs 100 By Actavis Pharma.

Estropipate 3 Mg Tabs 100 By Actavis Pharma.

Call for Price

Estropipate 3 Mg Tabs 100 By Actavis Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3322757/RXB10029890/RXA410046
Size : 100
Selling UoM : EA
NDC: 00591-0416-01
UPC Barcode : 305910416010
Supplier: 0050000679 ACTAVIS PHARMA INC/GENERIC
Supplier Material : 041601
Generic Code : 003243 ESTROPIPATE ORAL TABLET 3 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Generic RX

Have a question?

  Call for Price

Product Description.:

WATSON 416
tablet , blue , scored , round round

OGEN (estropipate tablets), (formerly piperazine estrone sulfate), is a natural estrogenic substance prepared from purified crystalline estrone, solubilized as the sulfate and stabilized with piperazine. It is appreciably soluble in water and has almost no odor or taste ? properties which are ideally suited for oral administration. The amount of piperazine in OGEN is not sufficient to exert a pharmacological action. Its addition ensures solubility, stability, and uniform potency of the estrone sulfate. Chemically estropipate, molecular weight: 436.56, is represented by estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-, compound with piperazine (1:1).

OGEN is available as tablets for oral administration containing either 0.75 mg (OGEN .625), 1.5 mg (OGEN 1.25), or 3 mg (OGEN 2.5) estropipate (Calculated as sodium estrone sulfate 0.625 mg, 1.25 mg, and 2.5 mg, respectively).

Inactive Ingredients

Each tablet contains: Colloidal silicon dioxide, dibasic potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and tromethamine.

OGEN .625 also contains: D&C Yellow No. 10 and FD&C Yellow No. 6.

OGEN 1.25 also contains: FD&C Yellow No. 6.

OGEN 2.5 also contains: FD&C Blue No. 2.

INDICATIONS

OGEN is indicated in the:

1. Treatment of moderate to severe vasomotor symptoms associated with the menopause.
2. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
4. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400?800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.

SIDE EFFECTS

See BOXED WARNINGS, WARNINGS and PRECAUTIONS.

The following additional adverse reactions have been reported with estrogens and/or progestin therapy.
Genitourinary system

Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow breakthrough bleeding spotting dysmenorrhea increase in size of uterine leiomyomata vaginitis including vaginal candidiasis change in amount of cervical secretion changes in cervical ectropion ovarian cancer endometrial hyperplasia endometrial cancer.
Breasts

Tenderness, enlargement, pain, nipple discharge, galactorrhea fibrocystic breast changes breast cancer.
Cardiovascular

Deep and superficial venous thrombosis pulmonary embolism thrombophlebitis myocardial infarction stroke increase in blood pressure.
Gastrointestinal

Nausea, vomiting abdominal cramps, bloating cholestatic jaundice increased incidence of gallbladder disease pancreatitis enlargement of hepatic hemangiomas.
Skin

Chloasma or melasma that may persist when drug is discontinued erythema multiforme erythema nodosum hemorrhagic eruption loss of scalp hair hirsutism pruritus, rash.
Eyes

Retinal vascular thrombosis steepening of corneal curvature intolerance to contact lenses.
Central nervous system

Headache, migraine, dizziness mental depression chorea nervousness mood disturbances irritability exacerbation of epilepsy dementia.
Miscellaneous

Increase or decrease in weight reduced carbohydrate tolerance aggravation of porphyria edema arthralgias leg cramps urticaria angioedema anaphylactoid/anaphylactic reactions hypocalcemia exacerbation of asthma changes in libido triglycerides.